Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

18-05-2020(Mon) 15-05-2020(Fri) 14-05-2020(Thu) 13-05-2020(Wed) 12-05-2020(Tue)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
9 Mar, 2020 (Monday)

            
HUANXI MEDIA(1003)
Analysis¡G
Huanxi Media Group (1003) is principally engaged in investment in film and TV programmes rights, and the operation of its streaming platform¡§huanxi.com¡¨ (Åw³ß­º¬M). For the six months ended 30 June, 2019, its revenue surged 11.58-fold to HK$1.068 billion when compared with the last corresponding period. The Group`s business achieved a turnaround with net profit of HK$321 million. The Group has commenced a strategic cooperation with Beijing ByteDance Network Technology Limited to arrange for cinema films to be broadcasted on the platforms under ByteDance, including but not limited to¡§Xigua¡¨(¦è¥ÊµøÀW) and¡§Toutiao¡¨(¤µ¤éÀY±ø). The market response was satisfactory, far exceeding its expectations. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $1.53, Target Price: $1.70, Cut Loss Price: $1.45


PA GOODDOCTOR(1833)
Analysis¡G
Ping An GoodDoctor is the largest Internet medical and health platform in China. Through the mobile platform, the company provides online medical and health services, such as family doctor services, consumer medical services, health malls, and health management and interaction. The company has established a nationwide network of medical service providers, covering approximately 3,100 hospitals (including more than 1,000 tertiary hospitals), as well as approximately 1,100 medical examination centers, 500 dental clinics and 7,500 pharmacies. The company`s family doctor service, mobile platform and service provider network make the company an important online portal entry, forming the company`s vibrant medical and health ecosystem. The breadth and depth of the company`s user base and user participation, technical strength and service provider network have formed substantial competition barriers.
Strategy¡G
Buy-in Price: $73.50, Target Price: $85.00, Cut Loss Price: $66.00



CEB WATER (1857.HK) - Results of 2019 exceed expectations, price and capacity both rise to promote development

Company Update

As of 2019, the company has invested and held 1 raw water protection project, 3 water supply projects, 96 municipal sewage treatment projects, 12 industrial wastewater treatment projects, 1 leachate treatment project, 8 reclaimed water reuse projects, 6 basin treatment projects and 2 sewage source heat pump projects, while undertaking 2 EPC projects and 1 O&M project. The total design capacity is 850,000 cubic meters of water per day, 5.14 million cubic meters of sewage per day, and 206.6 thousand cubic meters of reclaimed water per day. The sewage source heat pump project can provide heating and cooling services for an area of ​​295,000 square meters. It includes 101 operating projects, 1 completed project, 14 projects under construction, and 16 preparatory projects, of which the daily water treatment capacity of the preparatory projects reaches 1.15 million cubic meters.

In 2019, the company obtained a total of 18 new projects and signed a supplementary agreement, including 1 raw water protection project, 13 sewage treatment projects, 3 reclaimed water reuse projects, 1 sewage pipe network project and 1 existing Supplementary agreement for wastewater treatment projects. The newly increased capacity is 655,000 cubic meters of sewage per day, 85,000 cubic meters of daily water supply, 600,000 cubic meters of daily water supply, and 200 tons of daily sludge treatment and disposal. A total of 10 sewage treatment plants of the company were approved to raise water prices, with price adjustments ranging from 4% to 61%. A total of 18 projects of the company are under construction, with a design capacity of 354,100 cubic meters of sewage per day, 80,000 cubic meters of daily water supply, and 200 tons of sludge per day. 18 projects were completed and put into operation, with a design capacity of 440,000 cubic meters of sewage per day, 40,000 cubic meters of reclaimed water, 150,000 cubic meters of daily water supply, and 50 tons of sludge per day. 31 projects under construction, involving a daily water treatment capacity of about 790,000 cubic meters, and a daily sludge treatment of 250 tons. The company's operating projects have been steadily improved. In 2019, it will treat about 1.43 billion cubic meters of sewage and supply about 17.65 million cubic meters of reclaimed water, an increase of 13% and 10% year-on-year. The company's business capacity has steadily expanded. It has now spread to 10 provinces, municipalities and autonomous regions. Various engineering construction projects have been steadily advanced. The quality of operation and management projects has gradually increased, laying a foundation for the further development of the company's performance.

In 2019, the company recorded revenue of HKD 5.55 billion, a year-on-year increase of 16%, an increase of 2.4 percentage points from the first three quarters of 2019. The increase in revenue was mainly due to an increase of HKD 300 million in construction revenue, an increase of HKD 300 million in operating income, an increase of HKD 76 million in financial revenue, and an increase of HKD 99 million in technical services revenue, representing year-on-year growth of 11%, 25%, 10% and 98%. The above-mentioned increase in revenue was mainly due to the increase in new projects, the operation of some new projects and the increase in water prices of some projects. The company's gross profit was HKD 1.89 billion, a year-on-year increase of 17%, which was 2.1 percentage points lower than the growth rate of gross profit in the first three quarters of 2019. The gross profit margin was maintained at 34% because the revenue share of construction business (about 24% gross profit margin) and operating services (about 47% gross profit margin) was similar to the previous year. Among them, construction revenue, construction contract revenue and technical service revenue totaled approximately 58%. Profit attributable to equity holders of the company was HKD 830 million, an increase of 23% year-on-year, and an increase of 5.9 percentage points from the first three quarters of 2019. The company's various operating indicators exceeded our expectations, reflecting the company's good project growth and cost management capabilities.

We believe that the impact of the new pneumonia epidemic on the company is relatively limited. Although the shutdown of some industrial enterprises has affected the wastewater treatment capacity of the company's industrial park, a slight increase in municipal domestic sewage offsets this impact, and the industrial wastewater treatment capacity is expected to gradually recover in the near future, and I believe that it will soon return to normal levels. In terms of construction projects, the company's resumption of work after the holiday this year has been delayed compared to previous years, but it has gradually resumed work. I believe the government's encouragement of resumption of production will gradually ease the shutdown happening. In addition, the company's liability ratio increased slightly in 2019, an increase of 2.1 percentage points from last year to 57.9%. However, the return on shareholders` equity also increased by 1.4 percentage points to 9.9%, reflecting the improvement of the company's profitability. The dividend payout ratio increased slightly by 2 percentage points to 25%. The company's management believes that there is still room for improvement in the future dividend payout ratio. In addition, the company expects capital expenditure of approximately HKD 3 billion in 2020, which will maintain approximately the same growth rate as in 2019.

Adjust TP and maintain "BUY" Rating

We adjusted our forecast for FY20/FY21/FY22 incomes to HKD 5.936/6.416/7.004 billion, showing increases of 6.93%/8.09%/9.17% YoY; net profit attributable to shareholders were HKD 863/957/1,042 million, with increase of 3.52%/10.97%/8.82% YoY; the corresponding EPS was HKD 0.3090/0.3404/0.3677. The target price was adjusted to HKD 2.51, corresponding to FY20/FY21/FY22 8.11x/7.36x/6.81x PE, which was +47.39% higher than the current price (HKD 1.70 as of March 3, 2020), maintaining a ¡§BUY¡¨ rating.

Risk

Project progress fail expectations; Industry policy; M&A fails expectations.

Financials

Click Here for PDF format...




Recommendation on 9-3-2020
RecommendationBUY
Price on Recommendation Date$ 1.700
Suggested purchase priceN/A
Target Price$ 2.510
Writer Info
Leon Duan
(Research Analyst)
Tel: +852 2277 6515
Email:
leonduan@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2020 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]